GLYC: GlycoMimetics, Inc. Stock

by  •  • Comments Off on GLYC: GlycoMimetics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 17.00
Enterprise Value ($M) 6.28
Book Value ($M) 5.31
Book Value / Share 0.08
Price / Book 3.20
NCAV ($M) 5.31
NCAV / Share 0.08
Price / NCAV 3.20

Profitability (mra)
Return on Invested Capital (ROIC) -7.04
Return on Assets (ROA) -0.84
Return on Equity (ROE) -0.99

Liquidity (mrq)
Quick Ratio 1.92
Current Ratio 1.92

Balance Sheet (mrq) ($M)
Current Assets 11.09
Assets 11.09
Liabilities 5.78
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -32.51
Net Income -37.88
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -31.10
Cash from Investing 0.02
Cash from Financing 0.01

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Ra Capital Management, L.p. 0.00 -100.00
11-27 13G Logos Global Management LP 7.80
11-12 13G/A Invus Global Management, LLC 3.00 -62.84
11-04 13G/A Weinstein Benjamin 0.10 -98.53
11-04 13D Adage Capital Management, L.P. 7.90
05-08 13D/A New Enterprise Associates 10 L P

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-13 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Commission file number 001-36177 GlycoM
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-03-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number 001-36177 GlycoM

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-12 53,683 264,447 20.30
2025-03-11 27,701 149,782 18.49
2025-03-10 17,888 148,222 12.07
2025-03-07 49,041 133,384 36.77

(click for more detail)

Similar Companies
GLMD – Galmed Pharmaceuticals Ltd. GLSI – Greenwich LifeSciences, Inc.
GLTO – Galecto, Inc. GNLX – Genelux Corporation
GNPX – Genprex, Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: GlycoMimetics